Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.
Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
Type:
Grant
Filed:
March 8, 2021
Date of Patent:
August 8, 2023
Assignees:
Lubris LLC, Rhode Island Hospital
Inventors:
Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed, Joanna Szmydynger-Chodobska, Adam Chodobski
Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. The agonists are delivered to an individual at a dose sufficient to reduce hypertension and ischemic injury, and to reduce cardiotoxicity associated with chemotherapeutic agents.
Abstract: The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more of the following isolated amino acid sequences comprising or, alternatively, consisting of, SEQ. ID No.: 3, and/or SEQ. ID No.: 1, and/or SEQ ID No.: 2, kits and conjugates comprising one or more of the above mentioned amino acid sequences. In addition, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as a medicament, in particular in the treatment of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent. The present invention also provides a device for selective binding and separation of at least one component from an aqueous solution wherein the device comprises one or more of the above mentioned amino acid sequences.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
May 30, 2023
Assignee:
Sepsia Therapeutics, S.L.
Inventors:
Francisco Lozano Soto, Mario Martínez Florensa
Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.
Abstract: The present invention provides a composition that comprises at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines for the treatment of the hair, including animal and human hair, without the use of chemicals harmful to the hair fiber and consumer health and uses of said compositions in shampoo, lotion, serum, cream, conditioner, foam, elixir, oil, aerosol or mask.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
May 9, 2023
Assignee:
UNIVERSIDADE DO MINHO
Inventors:
Artur Manuel Cavaco Paulo, Celia Freitas Da Cruz, Margarida Maria Macedo Francesko Fernandes
Abstract: The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
May 9, 2023
Assignee:
The Regents of the University of Michigan
Inventors:
Anna A. Schwendeman, Yuqing Eugene Chen, Yanhong Guo, Jifeng Zhang, Wenmin Yuan, Emily Morin
Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
Type:
Grant
Filed:
September 30, 2020
Date of Patent:
April 25, 2023
Assignees:
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNLVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.
Abstract: Provided are a surfactant adhesive protein comprising an amphiphilic peptide, as a surfactant adhesive protein, at the carbon or amine terminal, a silicone oil and an anticancer composition comprising the surfactant adhesive, where the surfactant adhesive enables homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of the mussel adhesive protein, and the surface adhesive can be favorably used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
February 14, 2023
Assignee:
TME THERAPEUTICS CO., LTD.
Inventors:
Sang Jae Lee, Bong Jin Hong, Min Chul Park
Abstract: The present invention relates to methods and compositions for modulating mannosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process, using a polyether ionophore.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
January 31, 2023
Assignee:
ARES TRADING S.A.
Inventors:
David Bruhlmann, Thomas Vuillemin, Martin Jordan, Hervé Broly
Abstract: The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
January 10, 2023
Assignee:
AVIXGEN INC.
Inventors:
Yi Yong Baek, Woo Ri Shin, Si Eun Park, Jun Sub Choi, Hye Cheong Koo
Abstract: There is provided in the present application a pharmaceutical composition comprising a peptide comprising the amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant thereof, a pH adjusting agent, and a filler. The peptide is an active peptide for the treatment of a central nervous system injury. The present application also provides a pharmaceutical composition comprising a chimeric peptide comprising an active peptide and an internalization peptide, a pH adjusting agent, and a filler. The present application also provides medical use of a pharmaceutical composition comprising the active peptide or the chimeric peptide.
Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
December 27, 2022
Assignees:
CORNELL UNIVERSITY, UNIVERSITY OF WASHINGTON
Inventors:
Hazel H. Szeto, Peter S. Rabinovitch, Dao-Fu Dai
Abstract: The present invention provides compounds of formula (I) wherein X, L1 and R1 to R10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
November 22, 2022
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Konrad Bleicher, Daniella Cheang, Patrick Di Giorgio, Taishan Hu, Patrizio Mattei, Petra Schmitz, Theodor Stoll
Abstract: Pharmaceutical compositions including a mitochondria-targeting polypeptide and a therapeutic agent coupled to the mitochondria-targeting polypeptide are provided. Methods of treating a subject in need thereof including administering a therapeutically effective amount of the pharmaceutical composition to the subject are provided. The subject may have an aging-related condition, heart failure, diabetes, myocardial infarction, acquired mitochondrial disorder, and/or inherited mitochondrial disorder. Methods of delivering compound to a mitochondrion and of preparing a compound for delivery to a mitochondrion are also provided. Furthermore, biological tracers including a mitochondria-targeting polypeptide and a label coupled to the mitochondria-targeting polypeptide are provided.
Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3?-transgenic mice resist better to DSS-induced colitis after antibiotherapy.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
November 1, 2022
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITÉ PARIS-SUD
Inventors:
Joël Dore, Jamila Faivre, Nicolas Moniaux, Christian Brechot, Marion Darnaud
Abstract: The present invention provides a modified collagen comprising S-nitroso groups and a method of manufacture of such a modified collagen. Also provided is a wound dressing comprising such a modified collagen, particularly a wound dressing comprising a formulated composition comprising such a modified collagen.